Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-07-14
2008-11-11
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S617000, C514S618000, C564S154000, C564S155000, C564S158000
Reexamination Certificate
active
07449493
ABSTRACT:
The present application describes modulators of MCP-1 of formula (I):or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
REFERENCES:
patent: 5538997 (1996-07-01), Billich et al.
patent: 5710171 (1998-01-01), Dinsmore et al.
patent: 5770620 (1998-06-01), Mjalli et al.
patent: 5981491 (1999-11-01), Baxter et al.
patent: 6011052 (2000-01-01), Padia et al.
patent: 6028087 (2000-02-01), Bondinell et al.
patent: 6030946 (2000-02-01), Klaus et al.
patent: 6048861 (2000-04-01), Askew et al.
patent: 6084065 (2000-07-01), Cammaggi et al.
patent: 6100423 (2000-08-01), Collins et al.
patent: 6162790 (2000-12-01), Bemis et al.
patent: 6706712 (2004-03-01), Cherney
patent: 2003/0216434 (2003-11-01), Cherney
patent: 2004/0110736 (2004-06-01), Cherney
patent: 2004/0186143 (2004-09-01), Carter et al.
patent: 2004/0235835 (2004-11-01), Carter
patent: 2004/0235836 (2004-11-01), Cherney
patent: 2005/0043392 (2005-02-01), Carter
patent: 2005/0054626 (2005-03-01), Carter et al.
patent: 2005/0054627 (2005-03-01), Carter et al.
patent: 2005/0065147 (2005-03-01), Carter
patent: 0264795 (1987-10-01), None
patent: 443862 (1991-08-01), None
patent: 0731107 (1996-02-01), None
patent: 377869 (1991-06-01), None
patent: WO 199315047 (1993-08-01), None
patent: WO 199403479 (1994-02-01), None
patent: WO 199622966 (1996-08-01), None
patent: WO 199700894 (1997-01-01), None
patent: WO 9708145 (1997-03-01), None
patent: WO 199708145 (1997-03-01), None
patent: WO 199744329 (1997-11-01), None
patent: WO 199806703 (1998-02-01), None
patent: WO 199907351 (1999-02-01), None
patent: WO 199907678 (1999-02-01), None
patent: WO 199917790 (1999-04-01), None
patent: WO 199925686 (1999-05-01), None
patent: WO 199940913 (1999-08-01), None
patent: WO 199940914 (1999-08-01), None
patent: WO 99/46991 (1999-09-01), None
patent: WO 200042071 (2000-07-01), None
patent: WO 200046196 (2000-08-01), None
patent: WO 200069815 (2000-11-01), None
patent: WO 200069820 (2000-11-01), None
patent: WO 200250019 (2002-06-01), None
patent: WO 02060859 (2002-08-01), None
patent: WO 03075853 (2003-09-01), None
patent: WO 2004071449 (2004-08-01), None
patent: WO 2004071460 (2004-08-01), None
patent: WO 2004098512 (2004-11-01), None
patent: WO 2004098516 (2004-11-01), None
patent: WO 2005020899 (2005-03-01), None
patent: WO 2005021498 (2005-03-01), None
patent: WO 2005021499 (2005-03-01), None
patent: WO 2005021500 (2005-03-01), None
U.S. Appl. No. 10/776,828, filed Feb. 11, 2004, Cherney et al.
K. J. Kennedy et al., “Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1 α and monocyte chemotactic protein-1”, Journal of Neuroimmunology, vol. 92, pp. 98-108, 1998.
Fife et al., “CC Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis”, J. Exp. Med., vol. 192, No. 6, pp. 899-905, 2000.
Izikson et al., “Resistance to Experimental Autoimmune Encephalomyelitis in Mice Lacking the CC Chemokine Receptor(CCR)2”, J. Exp. Med., vol. 192, No. 7, pp. 1075-1080, 2000.
Tesch et al., “Monocyte Chemoattractant Protein 1-dependent Leukocytic Infiltrates Are Responsible for Autoimmune Disease in MRL-FAS1prMice”, J. Exp. Med., vol. 190, No. 12, pp. 1813-1824, 1999.
Andres et al., “Mice with a Selective Deletion of the CC Chemokine Receptors 5 or 2 Are Protected from Dextran Sodium Sulfate-Mediated Colitis: Lack of CC Chemokine Receptor 5 Expression Results in a NK1.1+Lymphocyte-Associated Th2-Type Immune Response in the Intestine,” The Journal of Immunology, vol. 164, pp. 6303-6312, 2000.
Jones et al., “Potential Role of Monocyte Chemoattractant Protein 1/JE in Monocyte/Macrophage-Dependant IgA Immune Complex Alveolitis in the Rat1”, The Journal of Immunology, vol. 149, No. 6, pp. 2147-2154, 1992.
Reinecker et al., “Monocyte-Chemoattractant Protein 1 Gene Expression in Intestinal Epithelial Cells and Inflammatory Bowel Disease Mucosa”, Gastroenterology, vol. 108, No. 1, pp. 40-50, 1995.
Grimm et al., “Enhanced Expression and Production of Monocyte Chemoattractant Protein-1 in Inflammatory Bowel Disease Mucosa”, Journal of Leukocyte Biology, vol. 59, pp. 804-812, 1996.
Russell et al., “Early and Persistent Induction of Monocyte Chemoattractant Protein 1 in Rat Cardiac Allografts”, Proc. Natl. Acad. Sci., vol. 90, pp. 6086-6090, 1993.
Antoniades et al., “Expression of Monocyte Chemoattractant Protein 1 mRNA in Human Idiopathic Pulmonary Fibrosis”, Proc. Natl. Acad. Sci., vol. 89, pp. 5371-5375, 1992.
Deleuran et al., “Localization of Monocyte Chemotactic and Activating Factor(MCAF/MCP-1)in Psoriasis”, Journal of Dermatological Science, vol. 13, pp. 228-236, 1996.
Gillitzer et al., “MCP-1 in mRNA Expression in Basal Keratinocytes of Psoriatic Lesions”, The Journal of Investigative Dermatology, vol. 101, No. 2, pp. 127-131, 1993.
Connor et al., “Change in Coreceptor Use Correlates with Disease Progression in HIV-1 Infected Individuals”, J. Exp. Med., vol. 185, No. 4, pp. 621-628, 1997.
Smith et al., “Contrasting Genetic Influence of CCR2 and CCR5 Variants on HIV-1 Infection and Disease Progression”, Science, vol. 277, pp. 959-964, 1997.
Havlioglu et al., “Slit proteins potential endogenous modulators of inflammation”, Journal of Neurovirology, 8: pp. 486-495, 2002.
Casnova et al., PubMed Abstract (Rev. Neurol. vol. 28(9): pp. 909-915, May 1999.
Bremner et al., “Therapy of Chron's Disease in childhood”, Expert. Opin. Pharmacother. vol. 3(7):pp. 809-825, 2002.
Beers et al., “Chron's Disease: Ulcerative Colitis: Psoriasis,” The Merck Manual of Diagnosis and Therapy, Seventeenth Edition (online), 1999.
Robinson et al., “Medical Therapy of Inflammatory Bowel Disease for the 21stCentury”, Eur. J. Surg., Suppl. vol. 582, pp. 90-98, 1998.
Singh et al., “Immune Therapy in inflammatory bowel disease and models of colitis,” British Journal of Surgery, vol. 88, pp. 1558-1569.
Ruminski et al., Chem. Abstract 126:264011, 1997.
Aleman et al., PubMed Abstract (Antivir. Ther. 4(2): 109-115), 1999.
Farber, PubMed Abstract (Braz. J. Med. Biol. Res. 31(1):11-17), Jan. 1998.
Baba et al., “A Small-Molecule, Nonpeptide CCR5 Antagonist With Highly Potent and Selective Anti-HIV-1 Activity”, Proc. Natl. Acad. Sci., May 1999, vol. 96, pp. 5698-5703.
Forbes, et al., “CCR2B Receptor Antagonists: Conversion of a Weak HTS it to a Potent Lead Compound”, Bioorganic and Medicinal Chemistry Letters, 2000, vol. 10, pp. 1803-1806.
Mirzadegan, et al., “Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists”, The Journal of Biological Chemistry, 2000, vol. 275, No. 33, pp. 25562-25571.
Carter Percy
Cherney Robert
Bogie Terence J.
Bristol-Myers Squibb Pharma Company
Bristol-Myers Squibb Pharmaceutical Company
Duncan Laurelee L.
Rao Deepak
LandOfFree
Diamines as modulators of chemokine receptor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diamines as modulators of chemokine receptor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diamines as modulators of chemokine receptor activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4033477